RxDoctor Payments Data

Chandrasekharan Krishnan, MD

Glaucoma Specialist · Boston, MANPI 1548225139

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $178 of the $223 with a category attached, or 79.8%. 4 manufacturers reported payments, led by AbbVie at 41.8% of the total. 2023 is the largest year on record at $112, 6.1 times the $18 reported in 2019.

$223in general payments, 2019–2025

Across 9 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$93
  • Novartis$89
  • Alimera Sciences, Inc.$23
  • Aerie Pharmaceuticals, Inc.$18

What the payments were for

  • Food & beverage$17880%
  • Gifts$4520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few glaucoma specialist providers in Massachusettsto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$264,764
Medicare patients
984
Services billed
2,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine58$78,612
LumiganBimatoprost115$70,413
RhopressaNetarsudil Mesylate56$32,975
Brimonidine Tartrate423$27,710
Cyclosporine37$26,857
Latanoprost1,170$20,661
CombiganBrimonidine Tartrate/Timolol28$20,616
Alphagan PBrimonidine Tartrate32$18,600
Travoprost68$15,160
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat651$13,570
RocklatanNetarsudil Mesylat/Latanoprost16$12,727
Timolol Maleate416$9,369
Prednisolone Acetate256$8,996
AzoptBrinzolamide23$8,485
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol35$7,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$93$188,240233 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$18$45,70372 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Massachusettson file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →